Briefing
Kadcyla and neratinib for interception of HER2-positive breast cancer with molecular residual disease
Phase 2 trial whose registry primary outcome is clearance of ctDNA, measured with the RaDaR assay, after neratinib is added to trastuzumab emtansine in people with detectable MRD. ClinicalTrials.gov lists the study as recruiting.
- Design: Phase 2 · Recruiting